Athira Pharma Inc

ATHA

Company Profile

  • Business description

    Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

  • Contact

    18706 North Creek Parkway
    Suite 104
    BothellWA98011
    USA

    T: +1 425 620-8501

    E: [email protected]

    https://www.athira.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    26

Stocks News & Analysis

stocks

Oracle shares are up 87% in 2025. Is it a buy?

Oracle’s cloud database business is riding the AI wave.
stocks

Bumper crop to benefit ASX listed share

We raise our earnings forecast 11% for next year.
stocks

Is there a long-term buying opportunity in luxury stocks?

Our analysts think the recent wobble in revenue growth is cyclical, not structural.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,141.6018.700.20%
CAC 407,830.1123.48-0.30%
DAX 4023,527.05112.36-0.48%
Dow JONES (US)46,381.5466.270.14%
FTSE 1009,226.6810.010.11%
HKSE26,080.30263.84-1.00%
NASDAQ22,788.98157.500.70%
Nikkei 22545,493.66447.850.99%
NZX 50 Index13,136.545.00-0.04%
S&P 5006,693.7529.390.44%
S&P/ASX 2008,850.6019.000.22%
SSE Composite Index3,788.0540.53-1.06%

Market Movers